For example, TLC-3595, from OrsoBio, Inc., is a selective ACC2 inhibitor showing promising results for treating type 2 diabetes by increasing fatty acid oxidation, reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver of Zucker Diabetic Fatty (ZDF) rats and db/db mice [62,63]. Here, INS is linked to type 2 diabetes mellitus.